InterCure Ltd. (INCR) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of InterCure Ltd. stock $10.06, price $3.63, upside +177.1%, quality 57 out of 100. Rating: strongly undervalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
InterCure Ltd.
INCR · USCheap (64% below fair value) and solid company, but falling price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
60‑month range $3.30 – $43.30 · fair‑value band $6.00 – $17.97 · the $3.63 price screens below the $10.06 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.
Every Wednesday you see whether InterCure is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Show moreShow less
It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Stock analysis
InterCure Ltd. (INCR) currently trades at $3.63, while our model-based Fair Value estimate is $10.06, implying the stock looks roughly 64% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $9.95 per share, and 8 of the 11 models we run sit above the $3.63 price.
Bear case: the Multiples group reads lowest at $4.06, and 3 of the 11 models stay below the price. Data coverage for this calculation is low.
Scenario range: $6.00 (bear) to $17.97 (bull), the price of $3.63 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2012: revenue and profit before it include the divested business. Growth is measured afresh from 2012.
InterCure Ltd. reported revenue of 270M ILS in FY2025 versus 220M ILS in FY2021, a compound +5.3%/yr. Reported net income was −35.7M ILS in FY2025.
Key figures
Market cap $54.5M Micro · P/S ratio 0.28 · EPS (TTM) $−0.9500 · Net margin −13.2% · Return on equity −9.3% · Return on assets (EBIT) −0.7% (5-year average) · Revenue (TTM) 243M ILS · Revenue growth (YoY) +23.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (low confidence).
What moves the price
The share trades about 50% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 177%, INCR screens cheaper than that median.
Fair Value models
All 12 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Watch INCR, get fair value alerts →
Compare InterCure Ltd. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Net margin by industry
- P/B ratio by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $84.39 | $113.53 | +35% | vs INCR |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.02 | ¥53.04 | +10% | vs INCR |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹1,983 | +6% | vs INCR |
| Haleon plc HLN | $9.20 | $8.47 | −8% | vs INCR |
| Merck KGaA MRK | €149.70 | €108.83 | −27% | vs INCR |
| Galderma Group GALD | CHF 191.00 | CHF 112.46 | −41% | vs INCR |
| Takeda Pharmaceutical Company TAK | $21.59 | $11.23 | −48% | vs INCR |
| Teva Pharmaceutical Industries Limited TEVA | $42.57 | $20.74 | −51% | vs INCR |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs INCR |
| Divi's Laboratories Limited DIVISLAB | ₹11,080 | ₹1,567 | −86% | vs INCR |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is InterCure Ltd. (INCR) overvalued or undervalued?
What is the fair value of INCR?
What is the quality score of INCR?
What is the price target for InterCure Ltd. (INCR)?
What is the InterCure Ltd. stock forecast for 2026?
What is the revenue of InterCure Ltd. (INCR)?
What growth is priced into InterCure Ltd. (INCR)?
What discount rate (WACC) does the fair value of INCR use?
What is a reverse DCF?
How much growth has InterCure Ltd. (INCR) delivered so far?
How fast is the sector of InterCure Ltd. (INCR) growing?
What is the free cash flow yield of InterCure Ltd. (INCR)?
What is the intrinsic value of InterCure Ltd. (INCR)?
Is InterCure Ltd. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of INCR?
How much is InterCure Ltd. worth?
What do the bullish and bearish scenarios say about INCR?
How solid is the balance sheet of InterCure Ltd. (INCR)?
How far is INCR from its 52-week high?
Which stocks are comparable to InterCure Ltd.?
Is InterCure Ltd. stock attractive at the current price?
How is the fair value of INCR calculated?
Is it still worth investing in stocks now?
What is the share price of InterCure Ltd. (INCR)?
What should I pay attention to with InterCure Ltd. right now?
Key figures of InterCure Ltd.
How large is the market capitalisation of InterCure Ltd. (INCR)?
What is the P/S ratio of InterCure Ltd. (INCR)?
What are the earnings per share of InterCure Ltd. (INCR)?
What is the net margin of InterCure Ltd. (INCR)?
What is the return on equity of InterCure Ltd. (INCR)?
What is the EBIT return on assets of InterCure Ltd. (INCR)?
How fast is revenue growing at InterCure Ltd. (INCR)?
How fast are earnings growing at InterCure Ltd. (INCR)?
How much net debt does InterCure Ltd. (INCR) carry?
Watch InterCure Ltd. in the live analysis
One click puts InterCure Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.